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Abstract 
The WT1 gene, localized on the 11p13 region of the human genome 
has an important role in the development of the urogenital system, but also in 
the regulation of cell proliferation and differentiation. WT1 gene is 
overexpressed in 70-90% of leukemic cells, irrespective of the type of 
leukemia. WT1 gene expression in peripheral blood may detect minimal 
residual disease in all types of leukemias. We measured the WT1 gene 
expression level with qRT-PCR in the peripheral blood of 34 patients with 
malignancies, mainly leukemias (2 AML, 2 CML, 2 NHL, 1 HD and 27 
ALL)  under cytostatic treatment, 13 oncological patients who completed 
their chemotherapy and were in remission and 21 patients suffering from 
non-malignant diseases. We found WT1 gene expressions in 19 PB samples 
out of 47 oncological patients: 17 WT1 expressions appeared in ALL 
patients (15 cases under treatment and 2 post treatment) and 1-1 in a CML 
and NHL patient. We found a significant inverse relationship between WT1 
gene positivity and time elapsed  between diagnosis and blood sample 
examination. We did not find any relationship between WT1 gene expression 
and age, gender, WBC at diagnosis, FAB type of lymphoblasts, 
immunophenotype, risk groups, survival rate and relapse. Repeated 
measurements of WT1 gene expression may become a useful tool in MRD 
monitoring, especially in leukemias which lack specific DNA markers.  
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Introduction 
 A zinc finger polypeptide gene (WT1 gene), at the human 
chromosome 11p13, plays an important role in normal kidney development. 
(Call et al.,1990).  Expression of WT1 gene was found in bone marrow 
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samples of acute myeloblastic leukemia (AML), acute lymphoblastic 
leukemia (ALL) and chronic myelocytic leukemia (CML) patients (Miwa, 
Beran & Saunders,1992), raising the possibility of its involvement in 
leukemia hematopoiesis. Inoue et al. (1994, 1996) suggested that quantitative 
WT1 gene expression can be used as a panleukemic marker for minimal 
residual disease (MRD) detection in acute leukemias. WT1 gene expression 
may be used for monitoring disease behavior (MRD, relapse) in leukemias, 
regardless of type and the presence or absence of DNA markers. (Keiholz et 
al., 2005; Kletzel, Olzewski, Huang,  & Chou, 2002). Exponential increase 
of WT1 gene expression precedes clinical relapse with several months, both 
in patients treated with chemotherapy and allogeneic bone marrow 
transplantation. (Ogawa et al., 2003). Expression of WT1 gene has been 
associated with chemoresistance in leukemias (Hirose, 1999).  
 The WT1 gene product is a regulatory molecule of cell growth and 
differentiation. In intrauterine life, WT1 is expressed primarily in the 
urogenital system. In adult life, WT1 gene expression is found in the 
urogenital system, central nervous system (SNC), bone marrow and lymph 
nodes. (Hirose, 1999). The WT1 gene located at chromosome 11p13 has 10 
exons, through two splicing events generates 4 variants with different 
functions. (Yang, Han, Saurez Saiz, & Minden, 2007). The N-terminus 
domain is involved in ribonucleic acid (RNA) and protein interactions. The 
C-terminus domain consists of 4 cysteine 2- histidine 2 zinc fingers, which 
bind to target DNA sequences and regulates many growth and differentiating 
factors (bcl-2, c-myc, IGF-II, IGF-I receptor, CSF-1, PAX-1, RAR-α). 
(Rosenfeld, Cheever, & Gaiger, 2003; Yang et al., 2007).  
 WT1 was first described as a tumor-suppressor gene in Wilms tumor. 
Inactivation of both alleles of WT1 gene resulted in Wilms tumor. Its 
function, however, is more complex and depends on the environment and 
tissue specificity. Wild-type WT1 gene is overexpressed in haematological 
cancers (AML, ALL, CML) and other cancers (lung, prostate, CNS, breast 
cancer, neuroblastoma, ovarian, pancreatic, desmoid tumor, etc.). 
(Hohenstein, & Hastie, 2006). WT1 gene is expressed in low levels in 
CD34+ primitive cells, probably induces a controlled self-renewal of cells. 
(Yang et al., 2007). In leukemias, it acts more likely as an oncogene. The 
precise mechanism of WT1 gene in leukemogenesis is not fully understood, 
however, a link between hematologic malignancies and WT1 gene 
expression level clearly exists.  
 WT1 protein-containing vaccines are currently under phase I/II/III 
evaluation; WT1 protein is immunogenic, it elicits a humoral and cytotoxic 
T-cell mediated immune response. (Maslak et al., 2010; Keiholz et al., 2009;  
Hashii et al., 2011; Gaiger et al., 1999). “WT1 is a promising tumor antigen 
for the development of a novel class of universal vaccines” (Van Driessche, 
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Berneman, & Van Tendeloo, 2012) and the National Cancer Institute named 
it as the most important antigen among 75, worth to investigate. (Brayer & 
Pinilla-Ibarz, 2013).  
 
Aim of the paper 
Monitoring childhood acute leukemias involve flow cytometry or 
PCR methods of bone marrow cells. PCR assessment is more sensitive but 
applicable only in a small percent of leukemias (20-30% in acute 
lymphoblastic leukemia), where specific fusion genes have been detected at 
the time of diagnosis. (Raso, Varga, Timar, & Magyarosy, 2000). In AML, 
more than 50%  of the patients lack clonality markers suitable for MRD 
monitoring. (Saglio et al., 2005). As WT1 gene is not expressed in normal 
peripheral blood cells (PB) (Saglio et al., 2005), we investigated the potential 
role of WT1 gene expression measurement from peripheral blood during the 
monitoring of childhood malignancies, mainly leukemias.  
 
Material and methods 
 WT1 gene expression was measured with quantitative real-time PCR 
analysis from the peripheral blood of 34 children treated for leukemias and 
lymphomas, 13 children with leukemias who have already finished their 
cytotoxic regimens and 21 children suffering from other non-malignant 
diseases. Two ml peripheral blood in EDTA tube was sent to the Molecular 
Biology Laboratory of our university for WT1 gene expression measurement 
with RT-PCR technique. RNA wasextracted from 1 ml blood with Qiamp 
RNA Blood Mini Kit (Qiagen Group), according to the manufacturer’s 
instructions. The RNA was diluted in 40 μL ultra pure water, and the RNA 
concentration was determined by NanoDropND–100 Spectrophotometer 
(Thermo Scientific, USA). Total RNA from each sample was used to 
synthesize cDNA using High Capacity cDNA Reverse Transcription Kit 
according to the manufacturer’s instructions (Applied Biosystems, USA) 
with Gene Amp PCR System 9700 (Applied Biosystems, USA). A final 
concentration of 1 μg/100 μL was obtained. TaqMan real-time quantitative 
PCR amplification reactions were carried out in an AB 7500 Real–Time 
PCR System (Applied Biosystems) using TaqMan Universal PCR Master 
Mix (Applied Biosystems) – 40 ng cDNA and 10 μL 2 × TaqMan Buffer 
with standard conditions (initial setup 2 minutes – 500C, 10 minutes – 950C, 
denaturation 15 seconds – 950C, annealing 1 minutes – 600C) and 50 cycles. 
ABL was used as reference gene with the following forward (f) and reverse 
(r) primers: (f),5’-TGGAGATAACACTCTAAGCATAACTAAAGG -3’; 
(r), 5’-GATGTAGTTGCTTGGGACCCA-3’; and the hybridization probe: F 
5’-CCATTTTTGGTTTGGGCTTCACACCATT-3 T’ (Applied Biosystems). 
WT1 expression was studied using  the following forward (f) and reverse (r) 
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primers: (f),5’-CAGGCTGCAATAAGAGATATTTTAAGCT-3’; (r), 5’-
GAAGTCACACTGGTATGGTTTCTCA -3’; and the hybridization probe: F 
5’-CTTACAGATGCACAGCAGGAAGCACACTG-3’ T (Applied 
Biosystems). All reactions were performed in a 20 μL volume with 6 pmol 
forward and reverse primer and 4 pmol TaqMan probe. All reactions were 
executed in triplicate. In the case of negative control, cDNA was not added. 
The relative quantification of WT1 gene expression was performed by 
calculating the concentration difference (Y) against the reference gene: Y = 2 
–ΔCt where ΔCt = Ct(WT1) – Ct(ABL); Ct – threshold cycle; 3. 32 cycle 
difference meaning 10-fold concentration difference. Non-parametric Mann-
Whitney and chi-square tests were applied for data processing.  
 
Results 
 The 3 groups in which WT1 gene expression level was measured from 
the peripheral blood of the patients were: 
 Group I consisted of 34 patients with malignancies who performed 
their  cytostatic regimens. Group II included 13 patients with malignancies 
after completion of their chemotherapy whom all were in complete 
remission. Group III included 21 patients admitted to the hospital with other 
non-malignant diseases. The follow-up time-span after WT1 gene 
assessment in all groups was 30 months. The cancer patients suffered from 
ALL (n=40), AML (n=2), non-Hodgkin lymphoma (n=2), Hodgkin disease 
(n=1) and CML (n=2), with a slight predominance of males (59, 6%). Six out 
of 40 patients with ALL belonged to high risk group (15%), bone marrow 
lymphoblasts were of L1 morphology in 43, 9% and L2 type in 56, 1% of the 
cases, whereas immunology of lymphoblasts showed the precursor B type in 
18 cases (48, 6%) and other, less favorable types including T-cell, CD10 
negative and biphenotypic cases, in 19 cases (51, 4%). The average age at 
diagnosis was 6,52 years (median 4,54 years), with a median number of 
leucocytes at presentation 17, 120/mm3 (range between 1200-424000/mm3). 
 We found 17 positive WT1 gene expression measurements in Group I, 
2 positive cases in Group II and other 2 positive results in Group III. In six 
patients, the WT1 gene expression was assessed at diagnosis, before any 
specific treatment, all results were positive, with higher quantitative 
expressions in high risk patients and T-cell ALL. After 1 month of 
antileukemic treatment, only 1 patient out of 6 had positive WT1 gene 
expression. Altogether we have found WT1 gene expressions in 19 PB 
samples of 47 oncological patients: 17 WT1 expressions appeared in ALL 
patients (15 cases under treatment and 2 post treatment) and 1-1 in a CML 
and NHL patient. We found a significant inverse relationship between WT1 
gene positivity and time elapsed between diagnosis and sample examination. 
The interval between diagnosis, and WT1 measurement varied between 0 
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and 180 months (mean 34, 25 months, median 26, 00 months; confidence 
interval 22, 12-46, 38 months). The mean time elapsed between diagnosis 
and WT1 gene expression measurement was 39, 18 months in WT1 negative 
cases (min 1, max. 180 months) and 23, 89 months in WT1 positive cases 
(min 0, max. 144 months), a statistically significant difference, non-
parametric Mann-Whitney test (p=0, 059).  
 
Figure 1. Correlation between WT1 gene expression in PB and time elapsed from 
diagnosis till WT1 measurement 
 
 We did not find any relationship between WT1 gene expression and 
age, gender, WBC at diagnosis, FAB type of lymphoblasts, 
immunophenotype, risk groups, survival rate and relapses.  Patients who 
expressed WT1 gene had a mean age at diagnosis of 6, 225 years, and those 
without WT1 expression of 6, 576 years. In WT1 positive cases the WBC at 
diagnosis was higher (mean 66.103, 33/mm3), versus  WT1 negative cases 
(mean WBC 56.441, 92/mm3), however, the difference is not statistically 
significant. More boys had WT1 gene expression in their PB samples than 
girls (50% versus 26, 3%), though the difference is not statistically 
significant (p=0, 104 Pearson chi-square test). In patients with absolute 
lymphoblast count (ALyC) above 1000/mm3 on day 8, fifty percent 
expressed WT1 gene in their PB, whereas this value was 40% in patients 
with ALyC < 1000/mm3. Correlated with FAB types of BM lymphoblasts, 
WT1 positivity had been found in 33, 3% of patients with L1 and 47, 8% of 
those with L2 type lymphoblasts. According to blast immunology, patients 
were assigned into 2 groups: one group with precursor B lymphoblasts 
(n=18) where the ratio of WT1 positivity was 38, 9% and the second group 
(n=19) with less favorable immunology (T-cell, CD10 negative precursor B 
cell lymphoblast, precursor B cell with myeloid markers) where WT1 
positivity reached higher ratio, 47, 4%. However, this difference is 
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statistically insignificant (Pearson chi-square test p=0,271). The 2 patients 
from Group II (leukemias in remission, after completion of therapy) who 
expressed WT1 gene in their PB (0, 051% and 0, 01%), were in 
hematological remission after 30 months of follow-up. In Group III we found 
2 positive WT1 results: 1 patient with immune thrombocytopenic purpura 
(WT1 0, 041%) and other with adenopathy-hepatomegaly-splenomegaly of 
viral origin (WT1 0, 001%), but none of them got sick of cancer during the 
following 30 months. One patient in whom MRD had been evidenced with 
PCR test, expressed WT1 gene in his peripheral blood sample in 0, 025% 
and continued specific treatment for additional 1 year, after which he became 
MRD-free. In 30 months time of follow-up, this patient is in remission. The 
17- year old adolescent girl with high-risk ALL who had a negative WT1 
expression result 12 months after diagnosis, relapsed at the end of 
maintenance therapy, underwent allogeneic bone marrow transplantation but 
died in refractory disease.  Among the two patients treated with CML, WT1 
gene expression correlated well with the level of BCR-ABL transcripts from 
peripheral blood. The patient who achieved major molecular response with 
BCR-ABL assessment by qRt-PCR was also negative for WT1 gene 
expression and the other patient who was positive for BCR-ABL 
rearrangement, had an elevated WT1 gene expression level (0, 190%) in his 
peripheral blood. This 12- year old boy with CML with positive WT1 result 
7 months after diagnosis, who received imatinib treatment but with episodes 
of non-compliance, died from disease progression. The WT1 positive 
patients and some of their disease features are presented in table 1.  
Table 1. Clinical and laboratory data of patients with WT1 expression in peripheral 
blood 
Idnr 
WT1 % 
PB 
Age at Dg 
yr Diagnosis 
WBC at 
Dg 
/μl 
AbsLyCd
8 FAB BM MO_imm 
Dg-
WT1int 
months Relapse 
30 44,840 8 ALL-T 211690 < 1000/μl L2 2 0 No 
21 41,870 13 ALL-B 21440 > 1000/μl L2 2 0 No 
32 05,140 16 ALL-T 68700 < 1000/μl L2 2 0 No 
16 00,850 11 ALL-T 239460 > 1000/μl L2 2 0 No 
12 00,400 2.02 ALL-B 18540 < 1000/μl L1 1 8 No 
5 00,250 4.08 ALL-B 1930 < 1000/μl L2 2 28 No 
22 00,190 12 CML 365770   2 7 Yes 
28 00,122 5 NHL     0 No 
24 00,092 12 ALL-B 2070 < 1000/μl L2 1 1 No 
33 00,066 7 ALL-B 2200 < 1000/μl L2 1 0 No 
          
8 00,051 4.05 ALL-B 8500 < 1000/μl L1 1 66 No 
18 00,046 2.6 ALL-B 12200 < 1000/μl L1 2 35 No 
1 00,025 5.10 ALL-B 9800 < 1000/μl L2 2 38 Yes 
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Idnr 
WT1 % 
PB 
Age at Dg 
yr Diagnosis 
WBC at 
Dg 
/μl 
AbsLyCd
8 FAB BM MO_imm 
Dg-
WT1int 
months Relapse 
11 00,010 6 ALL-B 6300 < 1000/μl L1 1 144 No 
7 00,007 2.02 ALL-B 8140 < 1000/μl L2 2 26 No 
8 00,007 2.04 ALL-B 14800 < 1000/μl L1  25 No 
13 00,001 5.04 ALL-B 159840 < 1000/μl L2 1 6 No 
34 00,001 4 ALL-B 8200 > 1000/μl L1 1 41 No 
17 00,001 4 ALL-B 30280 < 1000/μl L2 2 29 No 
Legend: AbsLyCd8= absolute lymphoblast count in peripheral blood on day 8; MO 
immunology 1= precursor B, 2= group consisted of T-cell, CD10 negative, aberrant myeloid 
markers; Dg-WTint months= time in months elapsed from diagnosis till WT1 gene 
expression measurement. 
 
Discussions 
Monitoring residual leukemic cells in bone marrow is important in 
assessment of treatment efficacy and prognosis. (Rak, 2001).  
Cytomorphological techniques offer detection of 1-5 malignant cells out of 
100 cells, immunophenotyping can detect 1 leukemic cell among 104 normal 
cells. (Braham et al., 2010). Revers-transcriptase polymerase chain reaction 
(PCR) based on demonstration of specific immunoglobulin heavy chain or 
TCR receptor gene rearrangements has slightly higher sensitivity. (Coustan-
Smith et al., 2002; Cavé,1999). However, the PCR technique necessitates the 
presence of fusion genes, like TEL-AML1, BCR-ABL, MLL-AF4 and 
others. These DNA markers are not found in all leukemias.  
To found a “panleukemic” marker, which reliably shows MRD and 
foresee an imminent relapse, which can easily be carried out from peripheral 
blood samples, has been tempting ever since the nineties, shortly after the 
discovery of the WT1 gene. It has been shown that WT1 gene expression 
appears in 70-90% of newly diagnosed leukemias, regardless of their type 
and the presence or absence of DNA markers. Its feature to decrease to very 
low levels or even disappear during remission, and reaching high levels 
several months before clinical relapse, qualifies WT1 gene as a sensitive tool 
in leukemia monitoring. In simultaneous measurements, WT1 levels 
mirrored the other molecular markers (where fusion gene transcripts were 
available for MRD assessment with qRt-PCR) where parallel assessments 
have been carried out. (Cilloni et al., 2002; Saglio et al., 2005, Kerst et al., 
2008).  
 WT1 gene expression has been found in all 6 ALL patients, who 
were assessed at diagnosis, before the introduction of chemotherapy. Other 
authors in larger patient groups found WT1 gene expression in 70-90% of 
acute leukemias.  
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After 1 month of chemotherapy, only 1 patient out of 6 expressed 
WT1 gene in 0, 092%. We found an inverse positive correlation between 
WT1 gene expression and time elapsed from diagnosis  (p=0, 059) (figure 1).  
Eleven patients were assessed after 8 months of chemotherapy, and 4 
of them expressed WT1 gene. Among the 20 patients assessed during the 9-
41 months of treatment, 7 cases were WT1 positive. Only 1 CML patient of 
these died from disease progression. The other patients have not experienced 
relapse during the 30 months follow-up. This may suggest that transitional 
WT1 gene expression may appear during maintenance therapy of ALL, 
without prognostic significance and the need of repeated WT1 measurements 
for MRD monitoring in leukemias. 
We measured increased quantitative WT1 gene expressions in 
patients with high WBC at diagnosis and T cell ALL, though the statistical 
results have not reached significant difference. Some authors have suggested  
that high WT1 expression at diagnosis is an unfavorable prognostic factor 
(Spanaki et al., 2007; Rosenfeld et al. 2003), while others have not found this 
association if intensive chemotherapy was applied. (Gaiger et al., 1999). In 
AML patients, pretreatment WT1 expression level was not prognostically 
predictive, but the kinetics of WT1 transcript reduction during treatment 
provided a more accurate prognostic factor. (Cilloni et al., 2009, Lapillonne 
et al., 2006).  
 In one of the 2 NHL patients, WT1 gene was expressed at diagnosis 
(0, 122%), though larger studies confirmed that in NHL WT1 gene 
expression is lower or absent because the malignant clone arises from more 
differentiated lymphoid cell. (Inoue et al., 1994) 
 We found no significant correlation between WT1 gene expression 
and age at diagnosis, gender, WBC count at presentation, FAB type, 
immunophenotype, risk groups, survival and relapses. Similar results were 
reported by other authors (Gaiger et al., 1999; Elmaagacli, Beelen,  
Trenschel & Schaefer, 2000) 
In the 2 CML patients, quantitative WT1 gene expression levels were 
concordant with the parallel BCR-ABL level measurements from PB. 
It has been shown that WT1 overexpression found in leukemic 
samples is related to the presence of leukemic cells and is not due to the 
immaturity of the cell population. (Saglio et al., 2005).  
Most observations related to WT1 gene expression have been made 
in adults. In pediatric leukemias, it has been shown that WT1 gene 
expression is higher in AML than ALL patients and FABL2 type compared 
to FABL1 type, in T-cell leukemia compared to B-cell ALL, in relapse 
versus diagnosis and in M1 FAB type versus M5 FAB. (Rosenfeld et al., 
2003; Rodrigues et al., 2007). 
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Conclusion 
WT1 gene was expressed in the PB in all 6 patients tested at 
diagnosis, before the introduction of chemotherapy. Chemotherapy as short 
as one month has led to undetectable WT1 gene levels in PB in the majority 
of patients. We found a positive inverse correlation between WT1 gene 
expression, and time elapsed between diagnosis and WT1 assessment. In 
CML patients, WT1 level showed good correlation with BCR-ABL levels in 
peripheral blood. WT1 gene expression may become a useful tool in MRD 
monitoring, especially in leukemias which lack specific DNA markers, but 
repeated measurements are mandatory to fulfill this aim. 
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